September 17, 2024 08:16 PM EDTUpdated 06:27 AM
People
Health Tech

All of 23and­Me's in­de­pen­dent board mem­bers re­sign over dis­agree­ments with CEO

Kyle LaHucik

Senior Reporter

All sev­en in­de­pen­dent di­rec­tors of 23andMe’s board have im­me­di­ate­ly re­signed, they wrote in a pub­lic let­ter Tues­day, ex­press­ing con­cerns over their …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Here's what to­day's Fed rate cut means for biotech, phar­ma and ven­ture cap­i­tal

FDA can­cels Ap­plied Ther­a­peu­tics ad­comm, shares sky­rock­et 65%

With few ef­fi­ca­cy de­tails, In­sil­i­co claims a Phase 2a win in lat­est AI read­out

You bet your life: Af­ter I was di­ag­nosed with a rare can­cer, I dis­cov­ered how a small band of physi­cian-sci­en­tists ...

Roivant makes an­oth­er deal, sell­ing Der­ma­vant to Organon for up to $1.2B

sponsored

Break­ing down si­los with a new quan­ti­ta­tive ap­proach to drug de­vel­op­ment

A service from the Financial Times